Allergan plc Ordinary Shares (AGN) was Reiterated by Leerink Partners to “Outperform” according to the research note released today. The brokerage firm has raised the Price Target to $ 294 from a previous price target of $272 . Leerink Partners advised their investors in a research report released on Jul 27, 2016.
Many Wall Street Analysts have commented on Allergan plc Ordinary Shares. Credit Suisse Initiated Allergan plc Ordinary Shares on Jul 25, 2016 to “Outperform”, Price Target of the shares are set at $327.Shares were Reiterated by Mizuho on May 13, 2016 to “Neutral” and Lowered the Price Target to $ 232 from a previous price target of $250 .
On the company’s financial health, Allergan plc Ordinary Shares reported $3.04 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on May 10, 2016. Analyst had a consensus of $3.01. The company had revenue of $3796.00 million for the quarter, compared to analysts expectations of $3949.70 million. The company’s revenue was up 48.1% compared to the same quarter last year.
Allergan plc Ordinary Shares closed down -4.68 points or -1.80% at $255.56 with 38,50,409 shares getting traded on Thursday. Post opening the session at $259.75, the shares hit an intraday low of $255.01 and an intraday high of $260.24 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
In a different news, on Jun 6, 2016, Maria Teresa Hilado (CFO) purchased 661 shares at $241.57 per share price. According to the SEC, on May 12, 2016, Nesli Basgoz (director) sold 459 shares at $225.10 per share price. On Aug 24, 2015, Brent L Saunders (CEO) purchased 1,000 shares at $301.94 per share price, according to the Form-4 filing with the securities and exchange commission.